Fabry disease – a multisystemic disease with gastrointestinal manifestations

Malte Lenders and Eva Brand

Internal Medicine D, Interdisciplinary Fabry Center Münster (IFAZ), University Hospital Münster, Münster, Germany

ABSTRACT
Nonspecific gastrointestinal (GI) symptoms, such as postprandial cramping pain, diarrhea, nausea and vomiting are typical symptoms for irritable bowel syndrome or inflammatory bowel disease, but may also be the first symptoms of Fabry disease (FD). This review focuses on GI manifestations in FD, by providing an overview of symptoms, a proper diagnosis, an appropriate management by FD-specific and concomitant medications and lifestyle interventions. We provide comprehensive literature-based data combined with personal experience in the management of FD patients. Since FD is rare and the clinical phenotype is heterogeneous, affected patients are often misdiagnosed. Consequently, physicians should consider FD as a possible differential diagnosis when assessing nonspecific GI symptoms. Improved diagnostic tools, such as a modified GI symptom assessment scale can facilitate the diagnosis of FD in patients with GI symptoms of unknown cause and thus enable the timely initiation of a disease-specific therapy. Expansive intravenous enzyme replacement therapy with α-galactosidase A or oral chaperone therapy for patients with amenable mutations improve the disease burden including GI symptoms, but a timely start of therapy is crucial for the prognosis. A special diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) or pre- and probiotics might improve FD-typical GI symptoms. Furthermore, preliminary success was reported with the oral administration of α-galactosidase A. In addition to a timely initiation of FD-specific therapy, affected patients with GI symptoms might benefit from a FODMAP-low diet, pre- and probiotics and/or low-cost oral substitution with AGAL to support digestion and reduce dysbiosis.

Introduction
Gastrointestinal (GI) symptoms of unknown causes often represent a time-consuming clinical-diagnostic challenge not only for gastroenterologists but also for general practitioners, internists, and pediatricians. Differential diagnoses include common diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), but also more rarely hereditary metabolic diseases such as Fabry disease (FD).

FD (Online Mendelian Inheritance in Man [OMIM] #301,500) is an X-chromosomal-linked inborn error due to various mutations within the α-galactosidase A (GLA/AGAL) gene, resulting in a deficient enzymatic AGAL activity. The worldwide incidence of FD has been estimated at 1 in 40,000 to 1 in 117,000 live male births. However, newborn screenings showed that the incidence of FD is more common, reporting 1:3,200 with the inclusion of late-onset and milder GLA variants.

To date, more than 1,000 GLA mutations have been identified, according to the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/), resulting in a wide spectrum of clinical symptoms and manifestations. Fabry-specific manifestations are a consequence of systemic accumulation of glycolipids (globotriaosylceramide [Gb₃]) mainly in the vascular endothelium, particularly in the kidneys, heart, nervous system, and skin alone or in combination with damage from deposits in almost all cell types (endothelial cells, nerve cells, muscle cells, among others). The progressive Gb₃ accumulation is accompanied by a high risk of early onset of stroke, life-threatening arrhythmia, myocardial infarction, or cardiac and renal failures. The deacylated and soluble form of Gb₃, globotriaosylsphingosine (lyso-Gb₃), seems to be a reliable biomarker for both disease progression and therapy efficacy, and is measured in blood plasma as well as urine.
In addition to renal, cardiac, and neurological manifestations, nonspecific GI symptoms including abdominal pain, diarrhea, constipation, bloating, nausea, and vomiting occur frequently and already appear in childhood. These symptoms often lead to a significantly reduced quality of life. Since FD is rare and the clinical phenotype is heterogeneous, affected patients are often misdiagnosed and therefore the diagnosis is delayed. In patients with milder or late-onset phenotypes, nonspecific GI symptoms can appear later in life (compared to classic phenotypes), leading to a diagnostic challenge, especially in those without a family history of FD.

FD is currently treatable by enzyme replacement therapy (ERT; agalsidase-alfa, 0.2 mg/kg body weight [b.w.] every other week [e.o.w.], and agalsidase-beta, 1.0 mg/kg b.w. e.o.w, intravenously)\textsuperscript{14,15} or chaperone therapy (oral migalastat 123 mg every other day)\textsuperscript{16} with estimated annual costs of ~250,000€ per year and patient in Europe. Safety and efficacy of both approved therapy strategies (ERT and chaperone) were repeatedly demonstrated, although their impact on disease progression is affected by various conditions including age and disease load at therapy initiation, dosage, sex, neutralizing anti-drug antibodies against ERT and type of GLA mutation. Since therapy is expensive, consensus recommendations for the initiation and cessation of ERT in patients with FD are published.\textsuperscript{17,18} Depending on sex and the extent of organ manifestation at the heart, kidney, and brain, Class I/II recommendations for an FD-specific treatment are proposed, clearly suggesting a beneficial impact on disease progression.\textsuperscript{17} In this respect, a Class I recommendation (FD-specific treatment is recommended/is indicated) is provided, if evidence and/or general agreement is present that a given treatment or procedure is beneficial, useful, and effective.\textsuperscript{17} A Class IIA recommendation (FD-specific treatment should be considered) is provided, if the weight of evidence or expert opinion is in favor of usefulness and efficacy. In addition, if the usefulness or efficacy of FD-specific treatment is less well established by evidence or expert opinion, a Class IIB recommendation (FD-specific treatment may be considered) is suggested. Treatment may be considered in patients with GI symptoms (Class IIA if <16 years of age, Class IIB if >16 years of age).\textsuperscript{17} Since GI symptoms severely reduce the quality of life, this may result in a therapeutic dilemma.

The aim of this review is to draw more attention to GI manifestations by providing an overview of GI symptoms in FD, a proper diagnosis and the pathophysiology with underlying mechanisms. We also provide an overview for an appropriate management and therapy strategies by FD-specific treatments, including concomitant medications and suitable lifestyle interventions, such as potential cost-effective diets and nutritional supplements, which might positively affect GI symptoms and increase patients’ quality of life.

**Clinical case**

For a better understanding of the clinical symptoms and complexity of FD diagnosis, the following clinical case may be helpful. A 38-year-old male patient presented to our Fabry center: during a dermatological treatment of a lichen sclerosus in the genital area, multiple angiokeratomas periumbilical and in the swim trunk area were noticeable, suggesting the differential diagnosis of FD. Since the age of eight, the patient suffered from mostly postprandial gastrointestinal cramping pain, flatulence, and diarrhea. He avoided food intake in the morning and at noon in order to be able to pursue his professional activity without gastrointestinal pain. There was underweight (body mass index 19 kg/m\textsuperscript{2}). Regarding the gastrointestinal complaints, multiple blood and stool diagnostics (Salmonella, Shigella, Campylobacter jejuni/coli, Yersinia), examinations regarding lactose and fructose intolerance, abdominal ultrasonography, several gastroscopies (no evidence of Helicobacter pylori) and coloscopies were without any indicative findings. The complaints were misdiagnosed as irritable bowel syndrome. Our diagnostic workup confirmed the suspected clinical diagnosis of FD with a markedly decreased enzymatic AGAL activity (<2.8 µmol/l/h; reference: ≥15.3 µmol/l/h), an increased lyso-Gb\textsubscript{3} (81 ng/ml, reference ≤1.8 ng/ml), and evidence of a pathogenic AGAL mutation (p.Arg112 Cys, hemizygous). Echocardiography revealed incipient left ventricular hypertrophy.
patients reported a prevalence of 51% for GI symptoms\(^{24}\) mainly due to abdominal pain and diarrhea.\(^{20}\) Abdominal pain is the most frequently reported symptom in affected patients and includes the appearance of colic with pain in the mid- or lower abdomen, bloating, cramping, or mid-abdominal discomfort.\(^{25,26}\) Since these symptoms may increase during or after meals or are triggered by stress, it is conceivable that many FD patients are reluctant to food intake, which may result in lower body weight. However, this seems to be limited to patients with very severe symptoms, since most studies and reports did not show differences in body mass index between patients with and without GI symptoms.\(^2\) Frequency and severity of diarrhea as the second most GI symptom is more diverse. According to the FOS registry, 20% of FD patients reported diarrhea, which was more common in males (26%) than in females (17%), and very frequent in children (25%).\(^{20,27}\) However, the real frequency in classical FD patients seems to be much higher, since the reported frequency in females with FD manifestations justifying ERT from the Fabry Registry is reported as 39%.\(^{23}\)

**Gastrointestinal symptoms in Fabry disease**

FD is a multisystemic disorder (Figure 1). GI symptoms belong to the first manifestations already in affected pediatric FD patients.\(^19\) Abdominal pain and diarrhea are the most common symptoms, followed by constipation, nausea, and vomiting.\(^{13,20–23}\) In detail, registry data from the Fabry Outcome Survey (FOS) based on 1,453

![Figure 1. Fabry disease is a multisystemic disorder.](image-url)
Diarrhea often appears postprandial (after food intake) and can occur up to 12 times a day, significantly reducing the quality of life of affected patients. Further symptoms include the appearance of nausea, vomiting (both more frequent in children) and constipation, while females seem to be more often affected by the latter than males. Mainly in adult patients, the presence of gastritis, hemorrhoids, chronic intestinal pseudo-obstruction, diverticular disease, and bowel ischemia was also reported.

**Pathophysiology and potential mechanisms**

Due to the complexity, the pathology of GI symptoms in FD is not very well understood, so far. Currently, five important non-exclusive mechanisms are supposed to be involved: i) dysfunction of the autonomic nervous system, adversely affecting gut motility, ii) vasculopathy, controlling GI blood circulation, iii) tissue inflammation, triggered by (lyso)-Gb₃ accumulation, iv) dysbiosis and bacterial overgrowth, v) lack of AGAL might result in a maldigestion of nutrition within the gut.

It is supposed that these processes may lead to a rapid intestinal passage as well as reduced intestinal peristalsis, intestinal stasis, pancreatic insufficiency, gastroparesis, an ischemic or neuropathic damage, and disturbed gut microflora balance, leading to GI symptoms and manifestations of FD.

Globotriaosylceramide (Gb₃) accumulation in muscle cells, endothelial cells, and nerve cells (submucosal and myenteric plexus) leads to enlargement of the villi, vasculopathy, and altered conduction of the enteric nerve signal, resulting in gastric dysfunction, including food malabsorption by the villi and postprandial abdominal pain, early satiety through food, nausea, and diarrhea, potentially leading to an imbalance of the gut microflora.

Dysmotility-induced high intraluminal pressure can lead to diverticula in the duodenum, jejunum, and colon with sometimes fatal consequences for affected patients. Pancreatic dysfunction may cause post-prandial diarrhea, especially after consumption of fatty meals.

FD is a small vessel disease due to the accumulation of Gb₃ within endothelial cells and smooth muscle cells, leading to endothelial dysfunction. The resulting vasculopathy in small vessels of the GI compartment may also lead to ischemic changes in the abdominal vasculature and could be responsible for observed GI symptoms including abdominal pain, impaired food absorption, and general inflammatory processes.

Recent studies have demonstrated an elevated inflammatory profile in patients with FD, but literature dealing with specific anti-inflammatory medication in patients with FD is scarce, and no specific recommendations for classes of anti-inflammation agents are currently suggested. In this respect, at least cell culture models for FD demonstrated an anti-inflammatory effect of pentosan polysulfate. However, non-steroidal anti-inflammatory drugs should be used with caution in patients with Fabry nephropathy, due to their potential nephrotoxicity.

Furthermore, a recent preliminary study also reported that lyso-Gb₃ modifies the biology of the gut microbiome, favoring the production of biofilms and altering the composition and short-chain fatty-acid profile of the gut microbiota. Finally, an increased accumulation of CD77 (Gb₃) on epithelial surface might also facilitate uptake and internalization of bacteriological enterotoxins, such as Shiga toxins as demonstrated for endothelial cells, resulting in a higher risk for bacterial-induced cell damage. Also, in this respect, the Gb₃ derivate isoglobotriaosylceramide was identified as a ligand for CD1d, which is involved in the activation of invariant natural killer T (iNKT) cells. The CD1d-dependent iNKT cell activation is part of the host defense in the intestine. Hence, it is likely that activation of iNKT cells leads to an altered (and thus increased) inflammatory state in affected FD patients, triggering GI symptoms.

In addition to a poor intestinal motility, recent studies suggest that lyso-Gb₃ directly affects microbiotical growth, which might eventually lead to dysbiosis, an imbalance of the intestinal flora. Dysbiosis is associated with an increased pro-inflammatory immune response, due to an abnormal proliferation of immune cells and increases the production of pro-inflammatory compounds, such as lipopolysaccharides. Gut dysbiosis furthermore
impairs the energy supply to the colonic epithelium and increases epithelial permeability, leading to a “leaky gut.” In this respect, lyso-Gb₃ increases the biofilm-forming capacity of several individual bacteria, including *Bacteroides fragilis*. In detail, lyso-Gb₃ also modifies the bacterial composition of the human colon microbiota suspension, increasing bacterial counts of *B. fragilis*, and modified the formation of short-chain fatty acids, leading to a striking decrease in butyrate concentration. In inflammatory bowel disease, dysbiosis can result in decreased energy procurement and also inflammation, which might also be true for FD. A dysbiosis in FD patients with renal impairment might further be triggered by an increased urea secretion into the digestive system, contributing to circulating uremic toxins, systemic inflammation, oxidative stress, cardiovascular events, and other complications as observed in patients with end-stage renal disease (ESRD).

GI symptoms in patients with FD might also be due to the lack of a proper galacto-oligosaccharide digestion within the intestine. In this respect, orally delivered AGAL digests and breaks down complex galacto-oligosaccharides (such as raffinose, stachyose, or verbascose), a process that probably reduces bowel symptoms including abdominal bloating and diarrhea by decreasing the colonic fermentation and thus gas production in patients with IBS.

**Diagnosis of Fabry disease**

Due to the variable clinical presentation, patients with FD often remain undiagnosed for many years. Delay in diagnosis of up to 20 years between the first symptoms and confirmed diagnosis is common. In patients with a long-term history of unexplained GI symptoms including postprandial abdominal pain, diarrhea, early satiety, gastroparesis, or chronic intestinal pseudo-obstruction FD should be considered for diagnosis. Furthermore, grouped angiookeratomas in the “swim trunks area” or umbilical could indicate FD. The presence of an ocular sign such as cornea verticillata, requiring a simple slit-lamp examination by an ophthalmologist, is also typical for a classical FD. Abnormal sweating (often hypohidrosis, occasionally hyperhidrosis), neuropathic pain in hands and feet triggered by temperature changes or fever (especially in the childhood) are typical symptoms of FD, too. In males, the determination of AGAL activity in blood leukocytes is the gold standard for a confirmation of the diagnosis. A pathologically low AGAL activity indicates the presence of FD. Subsequently, a genotyping should also be performed to determine the type of mutation, which is especially important for further FD-specific treatment options, such as chaperone therapy. In females, a molecular genetic testing with detection of a disease-causing mutation of the GLA gene is necessary to confirm the diagnosis, since females often have AGAL activities within the reference range. As a biomarker (marker of disease burden), pathologically elevated lyso-Gb₃ in plasma (or urine) will contribute to improve diagnosis and monitoring. Tissue biopsies may support diagnosis in uncertain cases, if multi-lamellar myelin bodies (so-called “zebra bodies”) are detected via electron microscopy. Although these “zebra bodies” are not pathognomonic of FD, their detection in relevant tissues obtained in the clinical context will suggest the diagnosis of FD and is recommended as the gold standard for the differential diagnosis of FD in adult subjects. Prenatal diagnosis can be performed by measuring AGAL activity in chorionic villi or cultured amniotic cells and, in the case of a mutation known in the family, by molecular genetic methods. Due to the multisystemic symptoms and manifestations of FD, clinicians should also evaluate if the patient suffers from additional manifestations such as renal or cardiac abnormalities, including loss of renal function (i.e. loss of eGFR, albuminuria/proteinuria), unexplained left ventricular hypertrophy, heart failure, and/or cardiac arrhythmia. A subsequent family history of such symptoms (or FD itself) is also highly warranted. The combination of GI symptoms and additional FD-typical manifestations increases the pretest probability of identifying an FD patient.

**Differential diagnosis**

Due to the varied and nonspecific GI symptoms, it is important to exclude other underlying diseases to avoid misdiagnosis in already diagnosed FD patients and those who have not yet been diagnosed. Thus, potential differential diagnoses of
adult patients with nonspecific gastrointestinal symptoms should include the following diseases:13 IBS (particularly diarrhea-predominant IBS), recurrent abdominal pain syndrome, chronic inflammatory bowel disease, appendicitis, Whipple’s disease, dermatomyositis, diverticular disease, somatoform disorder, Crohn’s disease, celiac disease, colon cancer, FD, mitochondrial diseases, transhyretin-related familial amyloid polyneuropathy. If no other reason for the observed symptoms is detected during endoscopy (gastroscopy, colonoscopy), biopsies with appropriate anti-Gb₃ immunostaining34 or electron microscopy56 can demonstrate the presence of Gb₃ deposits in epithelial gut cells of classical FD patients underlining the diagnosis of FD. In this respect, the requesting physician needs to include the differential diagnosis of FD in order to send an appropriately prepared biopsy for diagnosis, since routine biopsy will not detect FD.

Treatment of gastrointestinal symptoms in Fabry disease

FD is treatable by enzyme replacement therapy (ERT)14,15 or chaperone therapy.16 According to current European recommendations for patients with FD, the presence of GI symptoms that are not successfully treated with a symptomatic therapy justifies the initiation of an FD-specific therapy.17 Both cost-intensive ERT and chaperone strategies are reported to significantly improve FD-typical GI symptoms, such as diarrhea and abdominal pain. However, the impact of ERT on GI symptoms is heterogeneous, which is also represented by the class of recommendations (Class IIA/B).17 In addition, the socio-economic burden of expensive therapies, such as ERT and chaperone therapy (~250,000 €/year per patient) is also a matter of debate, especially if GI symptoms are the only detected manifestations in an affected patient. A general overview of the currently approved and potential future FD-specific treatments is provided in Table 1.

Impact of ERT on GI symptoms in FD

Treatment with either agalsidase-alfa (0.2 mg/kg b.w. e.o.w. intravenously; Replagal, Takeda) or agalsidase-beta (1.0 mg/kg b.w. e.o.w. intravenously; Fabrazyme, Sanofi Genzyme) was repeatedly reported to decrease frequencies of abdominal pain in affected adult and adolescent patients.20,21,23,32,59–63 Within the same studies, improvement of diarrhea21,23,32,59,62 nausea and vomiting,21,60,62 and constipation21,62 were observed. In addition, the dose or compound might affect the outcome for GI symptoms. In this respect, patients who received a reduced dose of agalsidase-beta (0.3 to 0.5 mg/kg b.w. e.o.w. intravenously) or those who were switched from agalsidase-beta (1.0 mg/kg b.w.) to agalsidase-alfa (0.2 mg/kg b.w.) during the worldwide shortage of agalsidase-beta reported an increase of gastrointestinal pain.64 However, not all patients benefit from ERT, and GI symptoms

### Table 1. Overview of current approved and potential future treatment approaches for Fabry disease.

| Approved | Non-approved |
|----------|-------------|
| **Treatment** | **Compound** | **Application** | **Cycle** | **Aim** |
| enzyme replacement therapy | agalsidase-alfa, agalsidase-beta | intravenous | every other week | replacement of deficient AGAL |
| chaperone | migalastat | oral | every other day | increase of endogenous AGAL activity |
| enzyme replacement therapy | pegunigalsidase-alfa, mossAGAL | intravenous | tba | replacement of deficient AGAL |
| substrate reduction therapy | venglustat, lucerastat | oral | every day | reduction of AGAL substrate |
| gene therapy | AVRO RD-01, ST920, FLT190, 4D-310 | lentiviral-, adenoviral-mediated | tba | genomic insertion of functional AGAL in certain cells (hPSC-, hepatocyte-or cardiomyocyte-targeted) |

AGAL: α-galactosidase A, tba: to be assessed.
are sometimes quite pronounced and relevant to daily life in ERT-treated patients, significantly reducing quality of life.

**Impact of pharmaceutical chaperone on GI symptoms in FD**

In addition to ERT, a second treatment option based on a pharmaceutical chaperone (oral migalastat 123 mg every other day, 1-deoxygalactonojirimycin (DGJ); Galafold, Amicus Therapeutics) is approved in Europe since May 2016, in Canada since September 2017, in Japan since March 2018 and in the United States since August 2018 for long-term treatment of FD in adults (≥18 years of age in the United States and Canada, ≥16 years in Japan, and ≥12 years in Europe) for patients with an amenable mutation and an estimated glomerular filtration rate (eGFR) ≥30 ml/minute per 1.73 m². Amenability, which means the response in terms of increasing enzymatic activities of an AGAL mutation to migalastat, is currently tested in a cellculture-based good laboratory practice (GLP)-assay. Although approved since 2016, data on the impact of migalastat on GI symptoms are still scarce. However, in classical previously ERT-untreated males with amenable mutations, an AGAL activity <3% of normal values and a multi-organ system involvement, migalastat treatment resulted in a significant reduction of GI symptoms measured via the Gastrointestinal Symptom Rating Scale (GSRS) after 24 months. In patients previously treated with ERT, migalastat led to an improvement in diarrhea based on the Minimum Clinically Important Difference (MCID) score compared to those receiving a placebo.

Despite FD-specific therapies with ERT or pharmaceutical chaperone, the impact of these drugs on GI symptoms is heterogeneous, probably due to the complexity of FD-related pathogenesis and mechanisms involved. Another reason is that GI symptoms that are pathogenically unrelated to FD cannot be improved by FD-specific treatments.

**Non FD-specific symptomatic treatment**

Some major GI symptoms in patients with FD can be treated with various concomitant drugs that are symptomatically effective. Patients with acute diarrhea can be treated with classical anti-diarrhea medication such as loperamide. By contrast, patients suffering from gastroparesis can benefit from treatments with pro-motility agents, such as metoclopramide, which increase the contractile force and accelerate intraluminal transit. Patients suffering from upper GI symptoms may benefit from proton pump inhibitors (e.g. omeprazole) or ondansetron if nausea is present. Medication against bloating and flatulence may include the administration of simethicone, which eliminates and prevents foam formation. Furthermore, linaclotide, which is an oligo-peptide agonist of guanylate cyclase 2C is used to treat IBS with constipation and chronic constipation with unknown cause. The anti-spasmodic dicyclomine, which blocks the action of acetylcholine on cholinergic receptors in smooth muscles in the GI tract, is used to treat spasms of the intestine in IBS, and might also be of relevance, although it should be used with caution, especially in patients with any unstable cardiac condition.

However, most of these medications are not suitable for long-term use due to side effects. Hence, non-drug management approaches including dietary modifications such as for patients with IBS are probably indicated, but require a therapy-adherent patient.

**Nutritional and dietary supplemental effects on GI symptoms in FD**

The effect of an AGAL deficiency on nutrition digestion has not been analyzed so far. To the best of our knowledge, no specific dietary interventions on FD patients have been reported, and recommendations are the same for IBS patients.

In general, appropriate recommendations for patients with IBS include a reduced intake of caffeine, alcohol, fat, and spicy food. Since irregular food intake deteriorates colonic motility and worsens IBS, FD patients should also follow a regular food intake (breakfast, lunch, dinner) and avoid larger meals. In addition, a special dietary seems advantageous. Recent studies demonstrated that patients with IBS benefit from a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP), since short-chain fermentable carbohydrates exert osmotic
effects that draw water into the intestinal and/or colonic lumen and FODMAPs that reach the distal ileum and colon undergo fermentation to short-chain fatty acids and gases, which can trigger GI symptoms\(^{76,77}\) (Figure 2). A general overview of food convenient for this diet is provided in Table 2. It is conceivable that especially FD patients might also benefit from this dietary approach, since many FODMAPs require AGAL for a proper digestion. In this respect, the classical Mediterranean, Okinawan, or anti-inflammatory diets are probably not recommendable due to the FODMAP-rich components such as legumes (beans, peas, chickpeas, soy, and lentils), whole grains, garlic, and so on. Compared to patients with IBS, after a 2–6-week elimination phase with a FODMAP-low diet, responding FD patients should undergo a reintroduction phase to determine which FODMAP-rich components are tolerated and which are not.\(^{77}\)

In addition, dietary supplements containing high amounts of orally delivered AGAL seem to be beneficial for gastrointestinal symptoms\(^{78,79}\) and further support the nutrition hypothesis. In a randomized double-blind placebo-controlled study, the administration of orally delivered AGAL significantly reduced breath hydrogen excretion and severity of flatulence in healthy volunteers during a meal containing 420 g cooked beans.\(^{79}\) Further studies demonstrated that non-FD patients with irritable bowel symptoms due to galacto-oligosaccharide intolerance may benefit from nutritional supplements containing high amounts of recombinant AGAL enzyme, an enzyme with amylase-like-activity.\(^{48,80}\)

Regarding the current literature, orally delivered AGAL might influence GI symptoms in patients with FD by a combination of several factors. First, orally delivered AGAL supports a proper digestion of nutrition. Second, a potential depletion of intestinal (lyso)-Gb\(_3\) might result in an amelioration of proinflammatory status and less dysbiosis. Third, if orally delivered AGAL is absorbed within the gut, this might lead to a depletion of Gb\(_3\) in, i.e., endothelial cells and neurons. In this respect, it is suggested that within the intestine AGAL digests and breaks down complex galacto-oligosaccharides (such as raffinose, stachyose, or verbascose), a process that probably reduces bowel symptoms including abdominal bloating and diarrhea by decreasing the colonic fermentation and thus gas production.\(^{65}\) In a recent case study, it was further...
Table 2. Overview of fermentable oligo-, di-, mono-saccharides and polyol (FODMAP)-rich and -low food and recommendations.

| Don’ts FODMAP-rich food | Do’s FODMAP-low food |
|-------------------------|---------------------|
| **fruits** (fructose, oligosaccharides, polyols) | apples, pears, apricots, cherries, dates, lychee, blackberries, currants, water melons, plums, mangoes, peaches, tinned fruits, fruit juices, dried fruits | lemons, oranges, tangerines, kiwi fruits, honey melons, pineapples, grape fruits, berries, passion fruits, papaya, rhubarb, bananas, grapes |
| **vegetables** (fructose, oligosaccharides, polyols) | asparagus, avocado, artichokes, beans, ch coercer, chickpeas, peas, onions, shallots, cauliflower, garlic, pickled cabbage, lentils, mushrooms, beetroot, savoy | salads, pak choi, cucumber, mangold, okra, zucchini, aubergine, sweet pepper, tomatoes, sprouts, olives, carrots, roots, potatoes, parsnips, radish, ginger, fennel, spinach, pumpkin, nori-algae, broccoli, green runner beans |
| **grains** (oligosaccharides) | gluten-reach grains (especially barley, wheat, rye) | gluten-free grains, millet, oat bran, spelt, corn, quinoa, amaranth, psyllium husks, buckwheat, rice, tapioca (manioc) |
| **sweeteners** (fructose, polyols) | corn syrup, fructose syrup, agave syrup, honey, mannitol sugar substitutes such as maltitol, isomalt, xylitol, sorbitol | little table sugar, glucose, maple leaf syrup, sugar substitutes such as aspartame |
| **dairy products** (lactose) | lactose containing milk and yogurt, cream cheese, cream, milk powder, sour cream | lactose-free milk and yogurt, hard cheese, brie, camembert, feta, mozzarella, coconut and soy milk, butter |
| **meat** | processed, fatty, fried or breaded meat, cold meat | lean meat, chicken, Turkey, eggs, lamb |
| **fish** | processed, fatty, fried or breaded fish | seafood every fish |
| **drinks** | lemonades, fruit juices, malt coffee, black tea (long drawn), fennel tea, chamomile tea beer, wine/sparkling wine (sweet, semi-dry), liqueur, rum, sherry | mineral water, carrot juice, cranberry juice, coffee, green and white tea, black tea (short infusion), peppermint tea, wine/sparkling wine (dry) |
| **other** | margarine, ketchup, cashews, pistachios | tofu, vinegar, olive oil, plant oil, rapeseed oil, mustard, less than 15 nuts per day, chocolate (dark) |

Demosntrated that daily oral substitution with oral AGAL can significantly decrease GI symptoms (diarrhea and abdominal pain) in FD patients. It is conceivable that the observed effects in this study are mainly due to an improved digestion of the food by the contained AGAL and beta-glucosidase. Hence, many GI symptoms in patients with FD might be due to the lack of a proper galacto-oligosaccharide digestion within the intestine due to absent or reduced AGAL activity, potentially leading also to an overgrown intestinal flora. Future studies are now warranted to confirm the effect of orally delivered AGAL on GI symptoms and gut microbiota in FD patients.

Due to existing dysbiosis, probiotics, and prebiotics may also alleviate gastrointestinal symptoms in FD patients. Probiotic bacteria are living microorganisms that can reduce dysbiosis, while prebiotics, as a substrate for intestinal healthy bacteria, promote the growth of Bifidobacteria, among others, and thus reduce bacterial dysbiosis.

Many probiotic bacteria are members of the gut microbiota and are included in foods to improve gut function. In this respect, the immunomodulatory ability of bacterial exopolysaccharides is reported. Consumption of food rich in probiotics or the supplementation of probiotics partially affected immune function by altering endogenous metabolic activities of microbiota. Interestingly (with respect to classical FD patients suffering from end-stage renal disease), probiotics were also reported to decrease pro-inflammatory cytokine levels (in blood) in patients undergoing dialysis. In addition, prebiotics such as polysaccharides from the green algae Enteromorpha clathrataprodive are a selective food base for intestinal bacteria such as Lactobacilli and Bifidobacteria and can specifically influence the composition of the intestinal flora, reducing dysbiosis by increasing microorganisms with a health-promoting influence in the colon.

**Hypothetic modifiers of GI symptoms in patients with FD**

Based on the current literature and on personal experience with affected patients, the following model of potential modifiers of GI symptoms in patients with FD could be assumed (Figure 3). Normal or FODMAP-rich nutrition will not be adequately digested within the gut, hypothetically due to the lack of functional (secreted) AGAL. In addition, lyso-Gb3 may promote dysbiosis. A FODMAP-low diet may reduce dysbiosis, although the effect of lyso-Gb3 on intestinal flora is still present. Treatment with migalastat was associated with a clearance of (lyso)-
Gb3 deposits from several cell types, including kidney peritubular capillaries, podocytes, endothelial cells and mesangial cells, and patient-derived urinary primary cells (in vitro), which might also result in an improved neuronal and vascular function in the intestine. It is conceivable that epithelial gut cells might also secrete functionally active AGAL to the gut lumen assisting in lyso-Gb3 decrease as well as nutrient digestion, which might result in reduced dysbiosis. However, future studies need to demonstrate whether endogenous AGAL will be secreted into the gut lumen or not and if the residual AGAL activity at neutral pH values in the intestine is sufficient. ERT results in intra- and extra-cellular (lyso)-Gb3 depletion comparable to chaperone therapy. Whether ERT also affects lyso-Gb3 or nutrient digestion in the gut lumen is questionable. Orally delivered (od)AGAL assists in FODMAP-rich nutrient digestion and potentially in lyso-Gb3 depletion within the gut lumen, both potentially indirectly reducing dysbiosis, too. If odAGAL will be internalized by epithelial gut cells and may deplete intra- and extra-cellular (lyso)-Gb3 afterward needs to be confirmed in further studies.

**Figure 3. Potential modifiers of GI symptoms in patients with FD.** Normal or FODMAP-rich nutrition will not be adequately digested within the gut, potentially due to the lack of AGAL. In addition, lyso-Gb3 promotes dysbiosis. A FODMAP-low diet will reduce dysbiosis, although the effect of lyso-Gb3 on intestinal flora is still present. Treatment with migalastat results in increased intra- and potentially extracellular AGAL activities and (lyso)-Gb3 depletion. Epithelial gut cells might also secrete functionally active AGAL to the gut lumen assisting in lyso-Gb3 decrease as well as nutrient digestion, which might result in reduced dysbiosis, but needs to be confirmed in appropriate studies. ERT results in intra- and extra-cellular (lyso)-Gb3 depletion. If ERT also affects lyso-Gb3 or nutrient digestion in the gut lumen is questionable, especially due to the nonacidic pH within the human intestine. Orally delivered (od)AGAL might assist in FODMAP-rich nutrient digestion and potentially in lyso-Gb3 depletion. Both could indirectly reduce dysbiosis due to the residual AGAL activity at neutral conditions, but needs further confirmation. If odAGAL will be internalized by epithelial gut cells and can deplete intra- and extra-cellular (lyso)-Gb3 afterward needs to be confirmed in further studies. AGAL: α-galactosidase A; ERT: enzyme replacement therapy; FODMAP: fermentable oligo-, di-, monosaccharides, and polyols; Gb3: globotriaosylceramide; lyso-Gb3: globotriaosylsphingosine; od: orally delivered.
Conclusion

Patients with FD often suffer from GI symptoms, such as abdominal pain, diarrhea, bloating, flatulence, nausea, and vomiting, which lead to a reduced quality of life. Therefore, physicians should also consider FD as a possible differential diagnosis when clinically assessing patients with unspecific upper and lower GI symptoms. Diagnostic tools such as patient-reported GI symptom questionnaires (such as GSRS) may aid the diagnosis of FD in patients with GI symptoms of unknown cause. In patients with unspecific GI symptoms, where FD is suspected on the basis of the clinical picture, FD diagnostics should be carried out by detection of a reduced AGAL activity in the blood (man) or molecular genetic detection of a causal GLA mutation (woman).

Several important FD-specific mechanisms such as dysfunction of the autonomic nervous system, vasculopathy, tissue inflammation, and dysbiosis are involved in GI manifestations and disease progression. It can be supposed that nutrition plays an important role, too. In addition to a timely initiation of FD-specific therapy, affected patients with GI symptoms might benefit from a FODMAP-low diet, pro- and prebiotics, and/or a cost-effective oral substitution with AGAL to assist a proper digestion. We conclude that FD patients with unspecific GI symptoms need more attention from treating physicians.

Disclosure statement

M.L. received speaker honoraria, travel funding, and research grants from Amicus Therapeutics, Sanofi Genzyme, and Takeda. E.B. received research grants and speaker honoraria from Sanofi Genzyme, Takeda, and Amicus Therapeutics.

Funding

The author(s) reported that there is no funding associated with the work featured in this article.

ORCID

Malte Lenders http://orcid.org/0000-0001-8409-2886

Data availability statement

No new data were generated or analyzed in support of this research.

Author contributions

Malte Lenders and Eva Brand wrote the manuscript.

References

1. Meikle PJ, Hopwood JJ, Clague AE, Carey, WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–254. doi:10.1001/jama.281.3.249.
2. Spada M, Pagliardini S, Yasuda M, Tukel T, Thigagarajan G, Sakuraba H, Ponzzone A, Desnick RJ. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40. doi:10.1086/504601.
3. Hopkins PV, Klug T, Vermette L, Raburn-Miller J, Kiesling J, Rogers S. Incidence of 4 lysosomal storage disorders from 4 years of newborn screening. JAMA Pediatr. 2018;172(7):696–697. doi:10.1001/jamapediatrics.2018.0263.
4. Schiffmann R. Fabry disease. Handb Clin Neurol. 2015;132:231–248.
5. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372(9647):1427–1435. doi:10.1016/S0140-6736(08)61589-5.
6. Auray-Blais C, Ntwari A, Clarke JT, Warnock, DG, Oliveira, JP, Young, SP et al. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta. 2010;411(23–24):1906–1914. doi:10.1016/j.cca.2010.07.038.
7. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, Ertl G, Wanner C, Weidemann F. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8–16. doi:10.1161/CIRCGENETICS.113.000249.
8. Auray-Blais C, Blais CM, Ramaswami U, Boutin, M, Germain, DP, Dyack, S et al., Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta. 2015;438:195–204. doi:10.1016/j.cca.2014.08.002.
9. Boutin M, Menkovic I, Martineau T, Vaillancourt-Lavigueur, V, Toupin, A, Auray-Blais, C. Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS/MS in urine of Fabry disease patients. Anal Chem. 2017;89:13382–13390.
10. Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab. 2017;120(1–2):57–61. doi:10.1016/j.mgen.2016.10.006.
11. Auray-Blais C, Lavoie P, Boutin M, Ntwari A, Hsu T-R, Huang C-K, Niu D-M. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clin Chim Acta. 2017;466:185–193. doi:10.1016/j.cca.2017.01.018.

12. Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuijlenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121(2):157–161. doi:10.1016/j.ymgme.2017.05.001.

13. Hilz MJ, Arbustini E, Dagna L, Gasbarrini A, Goizet C, Lacombe D, Ligouris R, Manna R, Politei J, Spada M, et al. Non-specific gastrointestinal features: could it be Fabry disease? Dig Liver Dis. 2018;50(5):429–437. doi:10.1016/j.dld.2018.02.011.

14. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan I, Linthorst GE, Desnick RJ. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med. 2001;345(1):9–16. doi:10.1056/NEJM200107053450102.

15. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743–2749. doi:10.1001/jama.285.21.2743.

16. Germain DP, Hughes DA, Nicholls K, Bichet D, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezugt F, Amartino H, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545–555. doi:10.1056/NEJMoA1510198.

17. Biegstraaten M, Arrgrimmson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendrikz C, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document. Orphanet J Rare Dis. 2015;10(1):36. doi:10.1186/s13023-015-0253-6.

18. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189–203. doi:10.1016/j.ymgme.2018.06.004.

19. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res. 2008;64(5):550–555. doi:10.1203/PDR.0b013e318183f132.

20. Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447–1453. doi:10.1016/j.cgh.2007.08.012.

21. Hughes DA, Barba Romero MÁ, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS—the Fabry outcome survey. Mol Genet Metab. 2011;103(3):207–214. doi:10.1016/j.ymgme.2011.03.022.

22. Pensabene L, Settoso S, Nicoletti A, Graziano F, Strisciuglio P, Concolino D. Gastrointestinal symptoms of patients with Fabry disease. Gastroenterol Res Pract. 2016;2016:9712831. doi:10.1155/2016/9712831.

23. Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz, A, Lemay, RM, Jovanovic, A, et al. Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with Agalsidase beta: data from the Fabry registry. JIMD Rep. 2018;38:45–51.

24. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009;46(8):548–552. doi:10.1136/jmg.2008.065904.

25. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750–760. doi:10.1136/jmg.38.11.750.

26. Zar-Kessler C, Karaa A, Sims KB, Clarke V, Kuo B. Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Therap Adv Gastroenterol. 2016;9(4):626–634. doi:10.1177/1756283X16642936.

27. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann, C, Beck, M et al. Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet. 2006;43(4):347–352. doi:10.1136/jmg.2005.036327.

28. Keshav S. Gastrointestinal manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 Years of FOS, Chapter 28. Oxford: PharmaGenesis. 2006.

29. Friedman LS, Kirkham SE, Thistlethwaite JR, Platika D, Kolodny EH, Schuffler MD. Jejunal diverticulosis with perforation as a complication of Fabry’s disease. Gastroenterology. 1984;86(3):558–563. doi:10.1016/S0016-5085(84)80028-1.

30. Jack CI, Morris AI, Nasmyth DG, Carroll, N. Colonic involvement in Fabry’s disease. Postgrad Med J. 1991;67(788):584–585. doi:10.1136/pgmj.67.788.584.

31. Buda P, Wieteska-Klimczak A, Ksiazyk J, Gietka, P, Smorczenewska-Kiljan, A, Pronicki, M et al. Gastrointestinal phenotype of Fabry disease in a patient with pseudodobstruction syndrome. JIMD Rep. 2012;4:25–28.

32. Politei J, Thurberg BL, Wallace E, Warnock D, Serebrinsky G, Durand C, Schenone AB. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet. 2016;89(1):5–9. doi:10.1111/cge.12673.
33. Politei J, Durand C, Schenone AB, Torres A, Mukdai J, Thurberg BL. Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases? Mol Genet Metab Rep. 2017;11:8–11. doi:10.1016/j.ymgmr.2017.03.004.

34. Di Toro A, Narula N, Giuliani L, Concardi M, Smirnova A, Favalli V, Urtis M, Alvisi C, Antoniazzi A, Arbustini E, et al. Pathologic substrate of gastropathy in Anderson-Fabry disease. Pathologic substrate of gastropathy in Anderson-Fabry disease. Orphanet J Rare Dis. 2020;15(1):156. doi:10.1186/s13023-020-01436-2.

35. Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76:246–251.

36. O’Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, Anholt L, Freeman H, Thomson ABR. Pathophysiology of the left ventricular cavity in patients with Fabry disease. J Mol Cell Cardiol. 1982;22(1):157–165. doi:10.1016/0022-2828(82)90262-X.

37. Dütsch M, Marthol H, Stemper B, Brys M, Haendt T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol. 2002;19(6):575–586. doi:10.1097/00004691-200212000-00011.

38. Burlina AP, Sims KB, Politei JM, Bennett, GJ, Baron, R, Sommer, C et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11(1):61. doi:10.1186/1471-2377-11-61.

39. Rombach SM, Twickler TB, Aerts JM, Linthorst, GE, Wijburg, FA, Hollak, CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99(2):99–108. doi:10.1016/j.ymgme.2009.10.004.

40. Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. Hum Mol Genet. 2015;24(20):5720–5732. doi:10.1093/hmg/ddv291.

41. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19–27. doi:10.1016/j.ymgme.2017.09.004.

42. Nordin S, Kozor R, Vijapurapu R, Augusto, JB, Knott, KD, Captur, G et al. Myocardial storage, inflammation, and cardiac phenotype in Fabry disease after one year of enzyme replacement therapy. Circ Cardiovasc Imaging. 2019;12:e009430.

43. Rickert V, Kramer D, Schubert AL, Sommer, C, Wischmeyer, E, Uçeyler, N. Globotriaosylceramide-induced reduction of KCa1.1 channel activity and activation of the Notch1 signaling pathway in skin fibroblasts of male Fabry patients with pain. Exp Neurol. 2020 Feb;324:113134. doi:10.1016/j.expneurol.2019.113134.

44. Crivaro AN, Mucci JM, Bondar CM, Ormazabal ME, Ceci R, Simonaro C, Rozenfeld PA. Efficacy of pentosan polysulfate in vitro and in vivo models of lysosomal storage disorders: Fabry and Gaucher Disease. PLoS ONE. 2019;14(5):e0217780. doi:10.1371/journal.pone.0217780.

45. Aguilera-Correa JJ, Madrazo-Clemente P, Martinez-Cuesta MDC, Peláez C, Ortiz A, Sánchez-Niño MD, Esteban J, Requena T. Lyso-Gb3 modulates the gut microbiota and decreases butyrate production. Sci Rep. 2019;9(1):12010. doi:10.1038/s41598-019-48424-4.

46. Schweppe CH, Bielaszewska M, Pohlenz G, Friedrich, AW, Büntemeyer, H, Schmidt, MA et al. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J. 2008;25(4):291–304. doi:10.1007/s10719-007-9091-7.

47. Zhou D, Mattner J, Cantu C 3rd, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu Y-P, Yamashita T, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science. 2004;306(5702):1786–1789. doi:10.1126/science.1103440.

48. van de Wal Y, Corazza N, Allez M, van de Wal Y, Mayer LF, Iijima H, Ryan M, Cornwall S, Kaiserlian D, Hershberg R, et al. Delineation of a CD1d-restricted antigen presentation pathway associated with human and mouse intestinal epithelial cells. Gastroenterology. 2003;124(5):1420–1431. doi:10.1016/S0016-5085(03)00219-1.

49. Feng Z, Wang T, Dong S, Jiang, H, Zhang, J, Raza, HK et al. Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature. J Int Med Res. 2021;49(10):300060552011053276. doi:10.1177/030006052011053276.

50. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen T-H, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–315. doi:10.1038/kid.2012.345.

51. Zhao J, Ning X, Liu B, Dong R, Bai M, Sun S. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi:10.1080/0886022X.2020.1864404.

52. Lee JS, Wang RX, Alexeev EE, Colgan SP. Intestinal inflammation as a dysbiosis of energy procurement: new insights into an old topic. Gut Microbes. 2021;13(1):1–20. doi:10.1080/19490976.2021.1880241.

53. Nguyen TTU, Kim HW, Kim W. Effects of probiotics, prebiotics, and symbiotics on uricemic toxins, inflammation, and oxidative stress in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(19):4456. doi:10.3390/jcm10194456.

54. Lenders M, Boutin M, Auray-Blais C, Brand, E. Effects of orally delivered alpha-galactosidase A on gastrointestinal symptoms in patients with Fabry disease. Gastroenterology. 2020;159(4):1602–1604. doi:10.1053/j.gastro.2020.06.007.
55. Hillilä M, Färkkilä MA, Sipponen T, Rajala, J, Koskenpato, J. Does oral α-galactosidase relieve irritable bowel symptoms? Scand J Gastroenterol. 2016;51(1):16–21. doi:10.3109/00365521.2015.1063156.

56. Marchesoni CL, Roa N, Pardal AM, Neumann, P, Cáceres, G, Martínez, P et al. Misdiagnosis in Fabry disease. J Pediatr. 2010;156:828–831.

57. Schifftmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med. 2016;18(12):1181–1185. doi:10.1038/gim.2016.55.

58. Oliveira JP, Ferreira S. <p>Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype–phenotype correlations. Appl Clin Genet. 2019;13:35–50. doi:10.2147/TACG.S146022.

59. Dehout F, Roland D, Treille de Granseigne S, Guillaume, B, Van Maldergem, L. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J Inherit Metab Dis. 2004;27(4):499–505. doi:10.1023/B: BOLI.0000037342.59162.69.

60. Wraith JE, Tytki-Szymanska A, Guffon N, Lien, YH, Tsimaratos, et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152(4):563–570. doi:10.1016/j.jpeds.2007.09.007.

61. Mougenot P, Lidove O, Caillaud C, Arnaud P, Papo T. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance. Eur J Clin Pharmacol. 2008;64(6):635–639. doi:10.1007/s00228-007-0460-8.

62. Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet. 2012;81(5):485–490. doi:10.1111/j.1399-3995.2011.01671.x.

63. Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard Lund A. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432–438. doi:10.1111/j.1399-3995.2012.01947.x.

64. Lenders M, Canaan-Kühl S, Krämer J, Duning, T, Reiermann, S, Sommer, C et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch - 2-year follow-up. J Am Soc Nephrol. 2016;27(3):952–962. doi:10.1681/ASN.2015030337.

65. Benjamin ER, Della Valle MC, Wu X, Katz, E, Pruthi, F, Bond, S et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430–438. doi:10.1038/gim.2016.122.

66. Germain DP, Nicholls K, Giugliani R, Bichet, DG, Hughes, DA, Barisoni, LM et al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019;21(9):1987–1997. doi:10.1038/s41436-019-0451-z.

67. Schifffmann R, Bichet DG, Jovanovic A, Hughes, DA, Giugliani, R, Feldt-Rasmussen, U et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13:68.

68. Argoff CE, Barton NW, Brady RO, Ziesmann, HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry’s disease: response to metoclopramide. Nucl Med Commun. 1998;19(9):887–891. doi:10.1097/00006231-199809000-00009.

69. Danhof IE, Stavola J. Accelerated transit of intestinal gas with salmethicone. Obstet Gynecol. 1974;44:148–154.

70. Friis H, Bodé S, Rumjens JJ, Gudmudnd-Hoyer E. Effect of Salmethicone on Lactulose-Induced H2 Production and Gastrointestinal Symptoms. Digestion. 1991;49(4):227–230. doi:10.1159/000200726.

71. Bassotti G, Usai-Satta P, Bellini M. Linaclotide for the treatment of chronic constipation. Expert Opin Pharmacother. 2018;19(11):1261–1266. doi:10.1080/14656566.2018.1494728.

72. Yang Y, Fang J, Guo X, Dai, N, Shen, X, Yang, Y et al. Linaclotide in irritable bowel syndrome with constipation: a Phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol. 2018;33(5):980–989. doi:10.1111/jgh.14086.

73. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3(2):153–156. doi:10.1097/00004836-198106000-00009.

74. Francini-Pesenti F, Ravarotto V, Bertoldi G, Spinella, P, Calò, LA. Could nutritional therapy take us further in our approaches to Fabry disease? Nutrition. 2020;72:110664.

75. Guo YB, Zhuang KM, Kuang L, Zhan Q, Wang X-F, Liu S-D. Association between diet and lifestyle habits and irritable bowel syndrome: a case-control study. Gut Liver. 2015;9(5):649–656. doi:10.5009/gtl13437.

76. Murray K, Wilkinson-Smith V, Hoad C, Costigan C, Cox E, Lam C, Marciani L, Gowland P, Spiller RC. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014;109(1):110–119. doi:10.1038/ajg.2013.386.

77. Liu J, Chey WD, Haller E, Esowan, S. Low-FODMAP diet for irritable bowel syndrome: what we know and what we have yet to learn. Annu Rev Med. 2020;71(1):303–314. doi:10.1146/annurev-med-052018-013625.

78. Ganiats TG, Norcross WA, Halverson AL, Burford, PA, Palinkas, LA. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract. 1994;39(5):441–445.
79. Di Stefano M, Miceli E, Gotti S, Missanelli, A, Mazzocchi, S, Mazzocchi, GR. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci. 2007;52(1):78–83. doi:10.1007/s10620-006-9296-9.

80. Tuck CJ, Taylor KM, Gibson PR, Barrett, JS, Muir, JG. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by α-galactosidase treatment. Am J Gastroenterol. 2018;113(1):124–134. doi:10.1038/jaig.2017.245.

81. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula IA, et al. World gastroenterology organisation global guidelines. Probiotics and Prebiotics October 2011 J Clin Gastroenterol. 2012;46(6):468–481. doi:10.1097/MCG.0b013e3182549092.

82. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66.

83. Jung YJ, Lee YT, Ngo VL, Cho, YH, KO, EJ, Hong, SM et al. Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection. Sci Rep. 2017;7(1):1–12. doi:10.1038/s41598-017-17487-8.

84. Tonetti FR, Islam MA, Vizoso-Pinto MG, Takahashi H, Kitazawa H, Villena J. Nasal priming with immunobiocic lactobacilli improves the adaptive immune response against influenza virus. Int Immunopharmacol. 2020;78:106115. doi:10.1016/j.intimp.2019.106115.

85. Galdeano CM, Cazorla SI, Dumit JML, Vélez E, Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019;74(2):115–124. doi:10.1159/000494624.

86. Wang IK, Wu YY, Yang YF, Ting I-W, Lin -C-C, Yen T-H, Chen J-H, Wang C-H, Huang -C-C, Lin H-C, et al. The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2015;6(4):423–430. doi:10.3920/BM2014.0088.

87. Shang Q, Wang Y, Pan L, Niu, Q, Li, C, Jiang, H et al. Dietary Polysaccharide from Enteromorpha Clathrata Modulates Gut Microbiota and Promotes the Growth of Akkermansia muciniphila, Bifidobacterium spp. and Lactobacillus spp. Mar Drugs. 2018;16(5):167. doi:10.3390/md16050167.

88. Mauer M, Sokolovskiy A, Barth JA, Castelli, JP, Williams, HN, Benjamin, ER et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet. 2017;54(11):781–786. doi:10.1136/jmedgenet-2017-104826.

89. Lenders M, Stappers F, Niemietz C, Schmitz, B, Boutin, M, Ballmaier, PJ et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56(8):548–556. doi:10.1136/jmedgenet-2019-106005.

90. Lieberman RL, D’aquino JA, Ringe D, Petsko GA. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 2009;48(22):4816–4827. doi:10.1021/bi9002265.